PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease
Authors:
- Naga ChalasaniNCNaga Chalasani
- Eduardo Vilar-GomezEVEduardo Vilar-Gomez
- Rohit LoombaRLRohit Loomba
- Anna Mae DiehlADAnna Mae Diehl
- Brent A. Neuschwander-TetriBNBrent A. Neuschwander-Tetri
- Srinivasan DasarathySDSrinivasan Dasarathy
- Kris V. KowdleyKKKris V. Kowdley
- Norah TerraultNTNorah Terrault
- Arun J. SanyalASArun J. Sanyal
- 23 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (5) , 1212-1226
Abstract
Background and Aims: The patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 variant is associated with steatotic liver disease and its progression. We examined the association between PNPLA3 and the development of major adverse liver outcomes (MALOs) and how nonmodifiable and modifiable conditions modify this relationship. Approach and Results: A total of 2075 adults with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled in the metabolic dysfunction-associated steatohepatitis Clinical Research Network (MASH CRN) studies and followed prospectively until death, transplant, or withdrawal of consent. One hundred four MALOs were recorded during an average of 4.3 years. PNPLA3 G-allele (Adj. sub-hazard ratio (sHR): 1.4, 95% CI: 1.07–1.8), advanced fibrosis (AF) (Adj. sHR: 7.8, 95% CI: 4.4–13.8), age >60 years (Adj. sHR: 2.9, 95% CI: 1.3–6.8), and type 2 diabetes mellitus (Adj. sHR: 2.8, 95% CI: 1.8–4.2) were associated with MALO. Among participants with AF, those carrying the G-allele displayed the highest cumulative incidence of MALO (85%) versus noncarriers (53%), p=0.03, and p-value for interaction PNPLA3 and MALO was statistically significantly greater among older than 60 years (sHR: 2.1, 95% CI: 1.5–2.8), women (sHR: 1.4, 95% CI: 1.1–1.9), and those with AF (sHR: 1.9, 95% CI: 1.5–2.4) or type 2 diabetes mellitus (sHR: 2.1, 95% CI: 1.5–2.8) as compared with their counterparts, p-value for interaction between PNPLA3 and each factorPNPLA3 rs738409 on the risk of MALO are significantly worsened by AF, age, type 2 diabetes mellitus, and sex.Keywords
This publication has 31 references indexed in Scilit:
- PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological featuresHepatology, 2022
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2020
- Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. PopulationHepatology, 2019
- Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational StudiesJAMA, 2019
- Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index CategoriesJAMA, 2013
- Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver diseaseHepatology, 2011
- Clinical, Laboratory and Histological Associations in Adults with Nonalcoholic Fatty Liver Disease†Hepatology, 2010
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005